Quebec, Canada
Medscint, founded in 2018 and headquartered in Canada, is at the forefront of developing innovative dosimetry solutions for the radiotherapy sector. Specializing in adaptable optical dosimetry, the company provides medical physicists with the tools to implement advanced radiation therapy techniques.
Their flagship product, the patented HYPERSCINT real-time dose measurement detectors, is renowned for its precision, particularly in complex scenarios such as small-field dosimetry, adaptive radiotherapy using MR-Linac, and ultra-high dose-rate FLASH-RT. This technology is already making substantial impacts across the United States, Canada, and Europe.
Medscint's ability to enhance cancer care outcomes positions it as a promising prospect, although it has yet to announce its latest investment rounds, leaving potential for strategic investment opportunities in the growing health care industry.
